Pub Date : 2019-02-18DOI: 10.26420/ANNHEMATOLONCOL.2019.1236
Sohn Sk
There is no standard therapy for relapse of acute leukemia after allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study evaluated the efficacy of Granulocyte Colony-Stimulating Factor (G-CSF)-Primed Donor Lymphocyte Infusion (DLI) for patients with acute leukemia who relapsed after allo-HCT. We retrospectively reviewed 255 patients who received allo-HCT for acute leukemia/myelodysplastic syndrome. They were divided into two groups based on the CD34 + cell dose they received; patients in the lower CD34 + group received less than 6×10 6 cells/kg and those in the higher group received over 6×10 6 cells/kg. No significant differences were noted between the groups with respect to overall survival, relapse-free survival, and Graft- Versus -Host Disease (GVHD)-free/relapse-free survival. Among the 93 patients with relapse after allo-HCT, 39 patients received G-CSF-primed DLI. These 93 patients were classified into early or late relapse groups as defined by the median time to relapse. In the late relapse group, the one-year overall survival was significantly higher in the DLI group than in the non-DLI group (53.4±7.4% vs . 26.7±7.4%, p=0.039), whereas there were no differences in the early relapse group. In addition, the incidence of DLI-induced GVHD did not differ between the two groups. In conclusion, treatment with G-CSF-primed DLI after allo-HCT with a limited CD34 + cell dose is a feasible and effective option, which may replace a second HCT in late relapse patients.
{"title":"Benefit of Granulocyte Colony-Stimulating Factor-Primed Donor Lymphocyte Infusion using Cryopreserved Cells for Patients with Acute Leukemia Who Relapsed Late after Hematopoietic Cell Transplantation","authors":"Sohn Sk","doi":"10.26420/ANNHEMATOLONCOL.2019.1236","DOIUrl":"https://doi.org/10.26420/ANNHEMATOLONCOL.2019.1236","url":null,"abstract":"There is no standard therapy for relapse of acute leukemia after allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study evaluated the efficacy of Granulocyte Colony-Stimulating Factor (G-CSF)-Primed Donor Lymphocyte Infusion (DLI) for patients with acute leukemia who relapsed after allo-HCT. We retrospectively reviewed 255 patients who received allo-HCT for acute leukemia/myelodysplastic syndrome. They were divided into two groups based on the CD34 + cell dose they received; patients in the lower CD34 + group received less than 6×10 6 cells/kg and those in the higher group received over 6×10 6 cells/kg. No significant differences were noted between the groups with respect to overall survival, relapse-free survival, and Graft- Versus -Host Disease (GVHD)-free/relapse-free survival. Among the 93 patients with relapse after allo-HCT, 39 patients received G-CSF-primed DLI. These 93 patients were classified into early or late relapse groups as defined by the median time to relapse. In the late relapse group, the one-year overall survival was significantly higher in the DLI group than in the non-DLI group (53.4±7.4% vs . 26.7±7.4%, p=0.039), whereas there were no differences in the early relapse group. In addition, the incidence of DLI-induced GVHD did not differ between the two groups. In conclusion, treatment with G-CSF-primed DLI after allo-HCT with a limited CD34 + cell dose is a feasible and effective option, which may replace a second HCT in late relapse patients.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44053919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.26420/ANNHEMATOLONCOL.2019.1235
P. Galieni
{"title":"Intermittent Low-Dose Thalidomide Plus Dexamethasone as Maintenance Therapy in Patients with Multiple Myeloma","authors":"P. Galieni","doi":"10.26420/ANNHEMATOLONCOL.2019.1235","DOIUrl":"https://doi.org/10.26420/ANNHEMATOLONCOL.2019.1235","url":null,"abstract":"","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45783177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-08DOI: 10.26420/ANNHEMATOLONCOL.2018.1234
B. Moiz
Standard thalassemia management is focused primarily on blood transfusions and iron chelation. Thalassemia caregivers grossly underestimate chronic pain due to bone and mineral related disorders. This study aimed to determine the frequency of bone pain, fractures, performance status and biochemical bone markers in children having transfusion dependent β-thalassemia major. We recruited 367 patients between 5 to 17 years of age from Fatimid Foundation Karachi, Pakistan. A questionnaire regarding clinical details such as demography, frequency of transfusion, iron chelation and fractures was administered. Wong-Baker Faces® pain rating scale and Eastern Cooperative Oncology Group Performance Status were used for assessment of bone pain and performance status respectively. Biochemical bone-health markers estimated included vitamin D, corrected calcium, intact parathyroid hormone, phosphorous, magnesium, zinc and ferritin levels. Among 367 children, 33.5% (n=123) were taking regular chelation and 50% (n=184) were on calcium and or vitamin D supplements. Eighty-two percent (n=303) patients experienced variable intensity of recurrent bone pain in past two years, which increased in frequency with advancing age. Forty-six patients (12.5%) reported multiple or recurrent fractures. Median 25OHD level was deficient (13.09ng/ ml IQR 18.6-8.56) with normal corrected calcium (8.81mg/dl IQR 9.4-7.97) while serum phosphate was at upper limit of reference range (5.1 IQR 5.9-4.3). Logistic regression analysis showed significant association of pain with age (OR 1.1 95% CI 1.0-1.2 p 0.001). The patients with and without fractures showed significant differences in age, corrected calcium, ferritin and zinc levels. Higher median phosphorus and iPTH were noted in patients with fractures but the difference was not significant. Binary logistic regression analysis showed statistically significant association with low levels of corrected calcium (OR 0.77% CI 0.6-0.9 p<0.04) and zinc (OR 0.08% CI 0.97-1.0 p<0.04). High prevalence of bone pains, fractures and biochemical abnormalities including hypovitaminosis D, hypocalcaemia and hyperphosphatemia were noted in patients with thalassemia. We need more studies to determine the impact on peak bone mass, prevalence of osteopenia and osteoporosis so that preventive intervention strategies can be planned in addition to adherence with optimum care for improving bone health in thalassemia.
{"title":"High Prevalence of Bone Pain and Fractures in Young Transfusion Dependent Patients with β-Thalassemia at Southern Pakistan","authors":"B. Moiz","doi":"10.26420/ANNHEMATOLONCOL.2018.1234","DOIUrl":"https://doi.org/10.26420/ANNHEMATOLONCOL.2018.1234","url":null,"abstract":"Standard thalassemia management is focused primarily on blood transfusions and iron chelation. Thalassemia caregivers grossly underestimate chronic pain due to bone and mineral related disorders. This study aimed to determine the frequency of bone pain, fractures, performance status and biochemical bone markers in children having transfusion dependent β-thalassemia major. We recruited 367 patients between 5 to 17 years of age from Fatimid Foundation Karachi, Pakistan. A questionnaire regarding clinical details such as demography, frequency of transfusion, iron chelation and fractures was administered. Wong-Baker Faces® pain rating scale and Eastern Cooperative Oncology Group Performance Status were used for assessment of bone pain and performance status respectively. Biochemical bone-health markers estimated included vitamin D, corrected calcium, intact parathyroid hormone, phosphorous, magnesium, zinc and ferritin levels. Among 367 children, 33.5% (n=123) were taking regular chelation and 50% (n=184) were on calcium and or vitamin D supplements. Eighty-two percent (n=303) patients experienced variable intensity of recurrent bone pain in past two years, which increased in frequency with advancing age. Forty-six patients (12.5%) reported multiple or recurrent fractures. Median 25OHD level was deficient (13.09ng/ ml IQR 18.6-8.56) with normal corrected calcium (8.81mg/dl IQR 9.4-7.97) while serum phosphate was at upper limit of reference range (5.1 IQR 5.9-4.3). Logistic regression analysis showed significant association of pain with age (OR 1.1 95% CI 1.0-1.2 p 0.001). The patients with and without fractures showed significant differences in age, corrected calcium, ferritin and zinc levels. Higher median phosphorus and iPTH were noted in patients with fractures but the difference was not significant. Binary logistic regression analysis showed statistically significant association with low levels of corrected calcium (OR 0.77% CI 0.6-0.9 p<0.04) and zinc (OR 0.08% CI 0.97-1.0 p<0.04). High prevalence of bone pains, fractures and biochemical abnormalities including hypovitaminosis D, hypocalcaemia and hyperphosphatemia were noted in patients with thalassemia. We need more studies to determine the impact on peak bone mass, prevalence of osteopenia and osteoporosis so that preventive intervention strategies can be planned in addition to adherence with optimum care for improving bone health in thalassemia.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45051145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-31DOI: 10.26420/annhematoloncol.2018.1225
E. Petru
Purpose: Ovarian cancer is usually diagnosed at advanced stage. Thus, recurrences are common. The aim of this retrospective study was to analyze the prognostic value of selected clinical and biological factors with regard to overall survival after first recurrence. Methods: A total of 368 evaluable patients with primary epithelial cancer of the ovary, fallopian tube or peritoneum were included. Carcinosarcomas, sarcomas and borderline tumors of the ovary, the fallopian tube and the peritoneum were excluded. Patient and tumor characteristics were extracted from hospital records. Recurrence was defined as the first clinical manifestation of tumor progression after an interval of no clinical evidence of disease following primary surgery. Patients with an elevated tumor marker CA125 alone and those who had clinically evident tumor after primary surgery were not eligible for this study. Results: In the multivariate cox regression analysis, five parameters were identified as independent favourable prognostic factors for survival after first recurrence: Time to recurrence ≥ 2 years (p=0.000), Karnofsky status ≥ 80% at the time of recurrence (p=0.008), use of adjuvant chemotherapy (p=0.013), residual disease ≤ 1 cm at primary surgery (p=0.044), and isolated peripheral or paraaortic lymph nodes as localization of first recurrence (p<0.05). Conclusions: Prolonged interval to recurrence seems to be of utmost importance for longer postrecurrence survival. In addition, small or no residual tumor after primary surgery, administration of adjuvant chemotherapy, higher performance status at recurrence and metastases in the peripheral or paraaortic nodes are predictive for improved overall survival.
目的:卵巢癌通常在晚期被诊断出来。因此，递归是常见的。本回顾性研究的目的是分析选择的临床和生物学因素对首次复发后总生存率的预后价值。方法:共纳入368例可评估的原发性卵巢、输卵管或腹膜上皮癌。排除卵巢、输卵管和腹膜的癌、肉瘤、肉瘤和交界性肿瘤。从医院记录中提取患者和肿瘤特征。复发被定义为原发性手术后一段时间无临床证据后肿瘤进展的第一个临床表现。单纯肿瘤标志物CA125升高的患者和原发性手术后出现临床明显肿瘤的患者不符合本研究的条件。结果:在多变量cox回归分析中，5个参数被确定为首次复发后生存的独立有利预后因素:复发时间≥2年(p=0.000)，复发时Karnofsky状态≥80% (p=0.008)，使用辅助化疗(p=0.013)，原发手术残留病变≤1 cm (p=0.044)，孤立的外周或主动脉旁淋巴结作为首次复发的定位(p<0.05)。结论:延长复发间隔似乎对延长复发后生存至关重要。此外，原发性手术后肿瘤小或无残留、给予辅助化疗、复发和外周或主动脉旁淋巴结转移时表现较好是提高总生存率的预测因素。
{"title":"Predictive Factors for Postrecurrence Survival in Epithelial Ovarian Cancer-a Consecutive Series of 368 Patients and Review of the Literature","authors":"E. Petru","doi":"10.26420/annhematoloncol.2018.1225","DOIUrl":"https://doi.org/10.26420/annhematoloncol.2018.1225","url":null,"abstract":"Purpose: Ovarian cancer is usually diagnosed at advanced stage. Thus, recurrences are common. The aim of this retrospective study was to analyze the prognostic value of selected clinical and biological factors with regard to overall survival after first recurrence. Methods: A total of 368 evaluable patients with primary epithelial cancer of the ovary, fallopian tube or peritoneum were included. Carcinosarcomas, sarcomas and borderline tumors of the ovary, the fallopian tube and the peritoneum were excluded. Patient and tumor characteristics were extracted from hospital records. Recurrence was defined as the first clinical manifestation of tumor progression after an interval of no clinical evidence of disease following primary surgery. Patients with an elevated tumor marker CA125 alone and those who had clinically evident tumor after primary surgery were not eligible for this study. Results: In the multivariate cox regression analysis, five parameters were identified as independent favourable prognostic factors for survival after first recurrence: Time to recurrence ≥ 2 years (p=0.000), Karnofsky status ≥ 80% at the time of recurrence (p=0.008), use of adjuvant chemotherapy (p=0.013), residual disease ≤ 1 cm at primary surgery (p=0.044), and isolated peripheral or paraaortic lymph nodes as localization of first recurrence (p<0.05). Conclusions: Prolonged interval to recurrence seems to be of utmost importance for longer postrecurrence survival. In addition, small or no residual tumor after primary surgery, administration of adjuvant chemotherapy, higher performance status at recurrence and metastases in the peripheral or paraaortic nodes are predictive for improved overall survival.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47784998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-26DOI: 10.26420/annhematoloncol.2018.1224
K. Derwich
Continuous development of effective antineoplastic therapies causes that immunodeficiencies are estimated to be one of the most vital problem of treatment. One of the possible keys for that could be Intravenous Immunoglobulins (IVIGs), but recommendations about substitution are not straightforward. if 4-5g/L is introduce a of pediatric patients with lack of unequivocal guidelines both should orientated in a role of on therapies and prevention for pediatric hemato-oncology
{"title":"IVIG in Immunocompromised Pediatric Patients - Advances and Prospects?","authors":"K. Derwich","doi":"10.26420/annhematoloncol.2018.1224","DOIUrl":"https://doi.org/10.26420/annhematoloncol.2018.1224","url":null,"abstract":"Continuous development of effective antineoplastic therapies causes that immunodeficiencies are estimated to be one of the most vital problem of treatment. One of the possible keys for that could be Intravenous Immunoglobulins (IVIGs), but recommendations about substitution are not straightforward. if 4-5g/L is introduce a of pediatric patients with lack of unequivocal guidelines both should orientated in a role of on therapies and prevention for pediatric hemato-oncology","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46277456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-08DOI: 10.26420/ANNHEMATOLONCOL.2018.1222
M. Farina
Seventy-two of 231 (31%) ASCT pts were > 65 yrs. Diagnosis was MM in 52 (72%) and NHL in 20 pts (28%) respectively. Median age was 69 (range 65-76). Patients’ comorbidities or significant laboratory abnormalities are summarized in (Table 1). Based on clinical judgement, conditioning regimen dose intensity was reduced in 10 pts (14%). In 12% (6/52) of MM pts melphalan dose was reduced to 140 mg/m2 (4) or 100 mg/m2 (2). FEAM dose was reduced at 75% in 4 NHL pts (20%) [1,2]. Pts achieved hematology recovery after a median of 10 days (6-13) and were discharged after 13 days (929). Infectious complications were the most frequent adverse event during the aplastic phase [3-5].
{"title":"Autologous Stem Cell Transplantation in Elderly Patients is Safe and is not associated with a Higher Frequency of Readmission Compared to Younger Patients. A Single Center Experience","authors":"M. Farina","doi":"10.26420/ANNHEMATOLONCOL.2018.1222","DOIUrl":"https://doi.org/10.26420/ANNHEMATOLONCOL.2018.1222","url":null,"abstract":"Seventy-two of 231 (31%) ASCT pts were > 65 yrs. Diagnosis was MM in 52 (72%) and NHL in 20 pts (28%) respectively. Median age was 69 (range 65-76). Patients’ comorbidities or significant laboratory abnormalities are summarized in (Table 1). Based on clinical judgement, conditioning regimen dose intensity was reduced in 10 pts (14%). In 12% (6/52) of MM pts melphalan dose was reduced to 140 mg/m2 (4) or 100 mg/m2 (2). FEAM dose was reduced at 75% in 4 NHL pts (20%) [1,2]. Pts achieved hematology recovery after a median of 10 days (6-13) and were discharged after 13 days (929). Infectious complications were the most frequent adverse event during the aplastic phase [3-5].","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41341741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-08DOI: 10.26420/ANNHEMATOLONCOL.2018.1223
J. Finlayson
{"title":"Disseminated Toxoplasmosis with Bone Marrow Involvement","authors":"J. Finlayson","doi":"10.26420/ANNHEMATOLONCOL.2018.1223","DOIUrl":"https://doi.org/10.26420/ANNHEMATOLONCOL.2018.1223","url":null,"abstract":"","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44018408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-02DOI: 10.26420/ANNHEMATOLONCOL.2018.1218
Keni Begendi N
Acquired Hemophilia A (AHA) is a rare but serious bleeding disorder caused by autoantibody (inhibitory) against factor 8 (FVIII). The incidence of the disease is increasing with age, and is seen between 9-15/1,000,000 over 65 years of the age, while it is about 0.3/1,000,000 per year under 65 years of the age. The patient and his family usually do not have any known bleeding diathesis [1,2]. The disease is idiopathic in 40-50% of the cases, while many etiological factors play a role in the remainder. The main etiological factors according to frequency can be listed as; autoimmune diseases, malignancies (solid tumors, hematological neoplasm’s), pregnancy, especially in the postpartum period, drugs, vaccination and respiratory system diseases [1,2]. AHA presenting with postpartum hemorrhage constitutes 6-21% of the all cases [3].
{"title":"A Rare Case of Acquired Hemophilia, Presenting with Postpartum Hemorrhage","authors":"Keni Begendi N","doi":"10.26420/ANNHEMATOLONCOL.2018.1218","DOIUrl":"https://doi.org/10.26420/ANNHEMATOLONCOL.2018.1218","url":null,"abstract":"Acquired Hemophilia A (AHA) is a rare but serious bleeding disorder caused by autoantibody (inhibitory) against factor 8 (FVIII). The incidence of the disease is increasing with age, and is seen between 9-15/1,000,000 over 65 years of the age, while it is about 0.3/1,000,000 per year under 65 years of the age. The patient and his family usually do not have any known bleeding diathesis [1,2]. The disease is idiopathic in 40-50% of the cases, while many etiological factors play a role in the remainder. The main etiological factors according to frequency can be listed as; autoimmune diseases, malignancies (solid tumors, hematological neoplasm’s), pregnancy, especially in the postpartum period, drugs, vaccination and respiratory system diseases [1,2]. AHA presenting with postpartum hemorrhage constitutes 6-21% of the all cases [3].","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42862236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-11-02DOI: 10.26420/ANNHEMATOLONCOL.2018.1219
G. Hyun
We describe a case of a 64-year-old woman who presented with isolated bilateral hypoglossal nerve palsy. After an extensive workup including an unremarkable Computed Tomography (CT) scan, she was found to have skull base metastasis from breast cancer on thin-slice Magnetic Resonance Imaging (MRI). This is the first reported case of isolated bilateral hypoglossal nerve palsy and demonstrates that thin-slice MRI provides.
{"title":"Bilateral Hypoglossal Nerve Palsy in a Patient with Breast Cancer","authors":"G. Hyun","doi":"10.26420/ANNHEMATOLONCOL.2018.1219","DOIUrl":"https://doi.org/10.26420/ANNHEMATOLONCOL.2018.1219","url":null,"abstract":"We describe a case of a 64-year-old woman who presented with isolated bilateral hypoglossal nerve palsy. After an extensive workup including an unremarkable Computed Tomography (CT) scan, she was found to have skull base metastasis from breast cancer on thin-slice Magnetic Resonance Imaging (MRI). This is the first reported case of isolated bilateral hypoglossal nerve palsy and demonstrates that thin-slice MRI provides.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41330511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-31DOI: 10.26420/annhematoloncol.2018.216
L. P
{"title":"De Novo Acute Myeloid Leukemia Involving only Granulocyte-Macrophage Line in Octogenarians with Leucocytes over 15 × 109/L Exhibit a Favorable Response to Standard-Dose Induction Chemotherapy","authors":"L. P","doi":"10.26420/annhematoloncol.2018.216","DOIUrl":"https://doi.org/10.26420/annhematoloncol.2018.216","url":null,"abstract":"","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49058805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：